Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies. This acquisition significantly increases Wyeth's already ...
Pittsburgh (ots/PRNewswire) - Mylan (NYSE: MYL) announced today that it has completed its acquisition of Merck KGaA's generics business ("Merck Generics") to become one of the largest quality generics and specialty pharmaceuticals companies in the world. Mylan and Merck KGaA initially announced the signing of a definitive agreement under which Mylan would acquire Merck Generics for EUR 4.9 billion (US$6.8 billion) ...
Pittsburgh (ots/PRNewswire) - Mylan Inc. (NYSE: MYL) today announced the appointment of Rajiv Malik as Executive Vice President in charge of Global Technical Operations. Mr. Malik has served in a similar capacity for Mylan since the Company acquired a controlling stake in Matrix Laboratories Limited (Matrix), where he is Chief Executive Officer, in ...
Pittsburgh (ots/PRNewswire) - - Promoted from Head of North America Mylan Inc. (NYSE: MYL) today announced the appointment of Heather Bresch as Chief Operating Officer. Ms. Bresch served previously as Head of North America and Chief Integration Officer. As Chief Operation Officer, Ms. Bresch will be responsible for Mylan's global commercial and technical operations, strategic planning, business development and ...
Pittsburgh (ots/PRNewswire) - Mylan Inc. (NYSE: MYL) today announced the appointment of Didier Barret to the position of President, EMEA (Europe, Middle East and Africa) following the completion of Mylan's acquisition of Merck's Generics Group today. At Merck Generics, M. Barret most recently served as Region Director, EMEA, reporting to the CEO. He was ...
All Eyes on Glaucoma(TM) Campaign
London (ots/PRNewswire) - - Global Advocacy Groups Launch Joint Effort to Preserve Eyesight of Millions At-Risk for Glaucoma Results of a new international survey reveal that eye exams are being ignored by many aged over 40. Only two fifths of respondents had visited an eye specialist in the last year to have their eyes checked, even though twice as many ...
Paris (ots/PRNewswire) - - New Design Offers Greater Flexibility in the Management of Patients With Complex Atherosclerosis Boston Scientific Corporation (NYSE: BSX) announced today that the Apex(TM) Monorail and Over-The-Wire (OTW) PTCA dilatation catheters have received CE Mark approval. Both Monorail and OTW catheters are available in two designs to ...
European Liver Patients Association (ELPA)
Brussels, Belgium (ots/PRNewswire) - - European Liver Patients Association Urges People at Risk to get Tested! A report(1) released today by the Eurasian Harm Reduction Network (EHRN)(i) highlights the significant inconsistencies that exist in hepatitis C (HCV) diagnosis and treatment across Europe and ...
London (ots/PRNewswire) - Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that Eisai has applied to the Court of Appeal for permission to appeal the recent High Court ruling on the process by which the National Institute for Health and Clinical Excellence (NICE) reached its ...
London (ots/PRNewswire) - - For the Attention of Business and Healthcare Editors Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya). ...
Cambridge, England (ots/PRNewswire) - - New Approach in the Development of Opioid-Based Pain Management Therapy Improves Bowel Function The oral prolonged-release (PR) oxycodone / naloxone combination tablet reduces opioid-induced bowel dysfunction in patients with chronic severe pain compared to ...
Barcelona, Spain (ots/PRNewswire) - - Abstract no: 2030, Being Presented at ECCO in the "Proffered Papers: Breast Cancer - Early Disease" Session in the Forum, Starting at 09.00am on Wednesday 26th September 2007 - For non-US Media Only New data show that the addition of Herceptin(R) (trastuzumab) ...
Boxmeer, The Netherlands and London (ots/PRNewswire) - Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT(TM) adjuvant for use in pandemic influenza ...
Boxmeer, The Netherlands (ots/PRNewswire) - A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund the research and the development ...
Siemens Medical Solutions Diagnostics
Tarrytown, New York (ots/PRNewswire) - - Advanced Network-Ready Diabetes Analysis for Better Patient Management Siemens Medical Solutions Diagnostics (www.siemens.com/diagnostics) today announced the launch of the DCA Vantage(TM) Analyzer, a point-of-care (POC) diabetes patient management platform ...
Barcelona, Spain (ots/PRNewswire) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ -- - 5 Year Data Confirm Superiority of Xeloda Over the Mayo Clinic Regimen in Treating Colon Cancer Five-year follow-up data from the X-ACT trial presented today ...
Barcelona, Spain (ots/PRNewswire) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ -- - 5 Year Data Confirm Superiority of Xeloda Over the Mayo Clinic Regimen in Treating Colon Cancer Five-year follow-up data from the X-ACT trial presented today ...
Barcelona, Spain (ots/PRNewswire) - - Largest Series of Patients With Successful Surgery Reported in Large, Prospective Clinical Trial - Abstract no: 3020, Being Presented at ECCO in Room 115-116, Starting at 12:15 on Monday 24th September 2007 - For non-US Media Only New data from the large international First BEAT trial unveiled today at the ...
Barcelona (ots/PRNewswire) - - For Medical and Healthcare Media Only - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Highlight the Need for More Positive Conversations Through Better Communication, Training and Use of Effective Treatments A devastating moment for a woman undergoing ...
Collegeville, Pennsylvania (ots/PRNewswire) - - European Committee Issues Negative Opinion on MYLOTARG(R) for Acute Myeloid Leukemia; Wyeth Plans to Appeal Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today that complete enrollment of its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer) ...
Honolulu, Hawaii (ots/PRNewswire) - - Protelos(R) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos(R) (strontium ranelate) stimulates bone formation and increases bone volume by 30% in high fracture risk patients who have been on long term ...
Takeda Pharmaceutical Company Limited
Amsterdam (ots/PRNewswire) - - For Non-US Media Only New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) (pioglitazone HCI) and its benefits regarding improved ...
Irvine, California (ots/PRNewswire) - - Leading Proxy Advisor Recommends Shareholders Support Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that Institutional Shareholder Services, ISS, a leading proxy advisor, recommends shareholders support the merger of IsoTis and Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra"). For every M&A analysis, ISS reviews publicly available information and evaluates ...
Pompey, France (ots/PRNewswire) - - Combined Company Will Become one of the Leading Suppliers for the Life Science Industries Groupe Novasep announced today that the company is finalizing discussions to acquire Bahamas-based PharmaChem Technologies (Grand Bahama) Ltd for an undisclosed amount. The combination of Novasep and PharmaChem responds to their ...
Alliance for Better Bone Health
Honolulu, Hawaii (ots/PRNewswire) - New data show that Actonel(R) 5mg (risedronate sodium tablets) reduces the risk of clinical fractures by half versus placebo over three years in postmenopausal women with osteoporosis who have suffered a previous hip fracture(1)- a group of patients at high risk of a subsequent fracture. These results are from a retrospective ...
Evry, France (ots/PRNewswire) - - Not for Distribution in the United States, Canada or Japan Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that the update of its document de base was filed on September 12th , 2007 to the Autorité des marchés financiers (AMF). This update ...
Basel, Switzerland (ots/PRNewswire) - - PROPHESYS Will Identify Factors That Influence Early Response to Treatment Roche announces the start of a large multinational observational study, called PROPHESYS, in patients with hepatitis C (HCV). This international cohort study will evaluate the important factors that give hepatitis C patients the best chance of treatment success with PEGASYS(R) (peginterferon ...
London (ots/PRNewswire) - AstraZeneca today announced enrolment of the first patient in the new GRAVITY study (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY). GRAVITY is a clinical trial examining the impact on LDL-cholesterol ('bad' cholesterol) levels in ...
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...